In 1996 PEA was proven to be orally active as an analgesic as well as an anti-inflammatory agent. That was based on the work of the Nobel Laureate Levi-Montalcini. PEA proved to be as effective as the NSAID painkiller indomethacine in this model. Here some details of this mile-stone paper. The main message is that PEA act as an analgesic and an anti-ionflammatory compound after swallowing PEA. So it is orally active. This is of importance, also for today.In 1996 co-workers of professor Rita Levi-Montalcini for the first time proved that palmitoylethanolamide is orally active in preventing mast cell degranulation provoked by inflammatory stimuli: exogenous substance P.
PEA also inhibited different aspects of the acute inflammatory response functionally correlated to mast cell activation produced by a number of inflammatory stimuli.
In a series of animal pain and inflammation experiments they demonstratd that the capability of palmitoylethanolamide to suppress extravasation (an inflammation marker) was, in the case of substance P, highly correlated with the reduced number of degranulated mast cells.
In 1993 Levi-Montalcini already demonstrated the anti-inflammatotory effects of PEA in an in-vitro model.
The open circles are PEA-related data and one can easily see the amount of edema reduction after oral PEA. PEA has been administered in these studies as the pure compound, not with any excipient added.